TheTechno Optimist.

Plozasiran (Redemplo)Arrowhead Pharmaceuticals—Health Canada issues Notice of Compliance for Redemplo (plozasiran) for familial chylomicronemia syndromePlozasiran (Redemplo)Arrowhead Pharmaceuticals—China NMPA approves Redemplo (plozasiran) for familial chylomicronemia syndrome; Sanofi to commercializePlozasiran (Redemplo)Arrowhead Pharmaceuticals—FDA approves Redemplo (plozasiran) for familial chylomicronemia syndrome

Arrowhead Pharmaceuticals

RNAi, siRNA, Redemplo, familial chylomicronemia

USpublic~711 staffest. 1989arrowheadpharma.com (opens arrowheadpharma.com)Checked 10 Oct

The brief

Analyst view
  • Redemplo (plozasiran) FDA-approved for familial chylomicronemia (Nov 2025); China and Canada approved in 2026.
  • Phase 3 PALISADE showed 80% triglyceride reduction in FCS, a severe rare lipid disorder.
  • Expanding to severe hypertriglyceridemia with ongoing Phase 3 program.

Technical approach

As reported
RNAi platform

TRiM silences disease genes

TRiM platform uses siRNAs that bind target mRNA and block cells from making proteins.

APOC3 target

Block triglyceride inhibitor

Plozasiran targets APOC3, which blocks triglyceride breakdown. Silencing it allows faster clearance.

Delivery

Liver-targeted injections

Plozasiran is a subcutaneous injection designed to reach the liver, where it silences APOC3 production. It is self-administered as a quarterly injection.

Primer